SMARCC2 and glioblastoma: In the present study, we demonstrate that the residual SWI/SNF group after SMARCC2 is specifically knocked out leads to the disorder of the genome, and perhaps the development of degraders targeting the residual SWI/SNF complex may be beneficial to SMARCC2-deficient glioblastoma.